Skip To Main Content
About
About Us
Board & Leadership
Publications
Patents
EMMs
Platform
Pipeline
Our Pipeline
AXA1125
AXA1665
Expanded Access Policy
Investors & News
Corporate Profile
Summary
News Releases
Events and Presentations
Stock Information
Financials & Filings
Corporate Governance
Historic Price
Investor Calculator
Quarterly Results
Analyst Coverage
Board & Leadership
Committee Composition
Careers
Contact
Flagship-founded Axcella to Test Midstage NASH Drug in Patients with Long COVID in Phase 2a Trial
